Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emmaus Sickle Cell NDA Facing FDA Concerns About Clinical Meaningfulness

Executive Summary

PGLG's application only has one Phase III trial, and Emmaus is hoping statistical re-analyses can address FDA skepticism about clinical meaningfulness of the primary endpoint data.


Related Content

Keeping Track: US FDA Approves Sickle Cell Therapy Endari; Array Submits Binimetinib Again
Modus's Intended IPO to Spur Sickle Cell Drug R&D
EPIC Fail For Mast Therapeutics’ Lead Drug Sends Shares Into Freefall
Keeping Track: New Drugs For Glaucoma, Sickle Cell Submitted; IDegLira, Brineura Reviews Extended; Keytruda Advances In First-Line NSCLC
L-glutamine positive for Emmaus, commercial prospects unclear
Sickle Cell Disease Orphan Status Lures Pharma Interest





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts